⚠ Evidence warning: Clinical trials or other evidence do not support the claim that passionflower has a legitimate role in benzodiazepine tapering protocols, or the claim that its benzoflavone reverses morphine, nicotine and cannabinoid tolerance (animal studies from one research group only; an independent laboratory found the benzoflavone only in trace amounts, in one of three herb samples). This page keeps it as a report of what people, websites or other media say.

Passionflower Gamma-Aminobutyric Acid (GABA) Modulation

gamma-aminobutyric acid Modulation — scientific infographic poster

The pharmacology of passionflower centers on the gamma-aminobutyric acid-A receptor, the principal inhibitory ionotropic receptor of the mammalian central nervous system. Wolfman and Medina's 1994 work isolated chrysin (5,7-dihydroxyflavone) from Passiflora coerulea and demonstrated it bound the benzodiazepine site of the gamma-aminobutyric acid-A receptor — the same allosteric pocket where diazepam, lorazepam, alprazolam, and zolpidem exert their effects. Dhawan's 2001 work proposed a second active scaffold, a benzoflavone moiety, after finding an anxiolytic fraction of the extract in mice; an independent laboratory later found a compound matching it only in trace amounts, in one of three herb samples. The combined effect of chrysin, benzoflavones, and several other flavone aglycones is partial-agonist potentiation of gamma-aminobutyric acid-A current, producing modest amplification of endogenous GABAergic inhibition without the powerful clamping effect of full benzodiazepine agonists. Beyond gamma-aminobutyric acid (GABA), passionflower also contains trace beta-carboline alkaloids (harman, harmine, harmaline, harmol) that are weak reversible inhibitors of monoamine oxidase A — the basis for theoretical interaction concerns with selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), and tyramine-containing foods. This deep-dive explores the receptor-level pharmacology, comparison with related botanical anxiolytics (apigenin/chamomile, bacopa, valerian), the harman alkaloid story, and what the multi-mechanism profile means for clinical use.


Table of Contents

  1. Gamma-Aminobutyric Acid-A Receptor Architecture and Allosteric Sites
  2. Chrysin (5,7-Dihydroxyflavone): The Principal BDZ-Site Ligand
  3. Benzoflavones: The Second Active Scaffold
  4. Comparison: Apigenin (Chamomile) and Bacopa
  5. Non-Benzodiazepine-Site Gamma-Aminobutyric Acid-A Modulation
  6. Harman Beta-Carboline Alkaloids and MAO-A
  7. Why Partial Agonism Produces Gentler Effects
  8. Tolerance, Dependence, and Withdrawal Profile
  9. Flumazenil Blocked Chrysin and the Whole Extract in Mice
  10. Theoretical and Real Drug Interaction Concerns
  11. GABA Itself Is in the Extract
  12. Key Research Papers
  13. Connections
  14. Featured Videos

Gamma-Aminobutyric Acid-A Receptor Architecture and Allosteric Sites

The gamma-aminobutyric acid-A receptor is a pentameric chloride-channel ligand-gated ion channel, the dominant fast-inhibitory neurotransmitter receptor in the mammalian central nervous system. Each receptor is built from five protein subunits drawn from a family of 19 known mammalian subunits (alpha1-6, beta1-3, gamma1-3, delta, epsilon, theta, pi, and rho1-3). The most common configuration in adult cortex is 2×alpha, 2×beta, and 1×gamma2, typically with the alpha1 subunit subtype, though other compositions (alpha2, alpha3, alpha5, delta-containing) predominate in specific brain regions and produce distinct pharmacology.

When gamma-aminobutyric acid binds the orthosteric site (located at the alpha-beta subunit interface), the chloride channel opens, chloride flows into the neuron, the neuron hyperpolarizes, and excitability decreases. This is the basic inhibitory function. Multiple allosteric sites on the receptor modulate this response, increasing or decreasing the chloride current produced by a given amount of orthosteric gamma-aminobutyric acid. The pharmacologically important allosteric sites include:

Passionflower's primary action is at the benzodiazepine site through chrysin and related flavones, with additional activity at non-benzodiazepine-site allosteric pockets through other flavone aglycones (discussed below). This multi-site profile is what distinguishes botanical gamma-aminobutyric acid modulation from single-target pharmaceutical benzodiazepines.

Back to Table of Contents

Chrysin (5,7-Dihydroxyflavone): The Principal BDZ-Site Ligand

Chrysin is a flavone (a subclass of flavonoid) with the structural formula 5,7-dihydroxyflavone — a relatively simple flavone with two hydroxyl groups on the A-ring and no substitution on the B-ring. It is widely distributed in plants and is found in honey, propolis, passionflower, and other botanical sources. Medina and colleagues first demonstrated in 1990 that chrysin bound the central benzodiazepine receptor with measurable (though modest) affinity in rat brain membrane assays (Ki = 3 µM at the central site and 13 µM at the peripheral site). Wolfman et al. extended this in 1994 by isolating chrysin from Passiflora coerulea and demonstrating anxiolytic effects in the elevated plus maze in mice at 1 mg/kg, with the effect abolished by pretreatment with the benzodiazepine-receptor antagonist Ro 15-1788 (flumazenil) — pointing to the BDZ-site mechanism. In the same study, chrysin at 0.6–30 mg/kg produced no muscle-relaxing effect in the horizontal wire test, while diazepam at 6 mg/kg did, and the authors postulated that chrysin is a partial agonist of the central benzodiazepine receptor.

The pharmacologic profile of chrysin at the BDZ site is partial-agonist with low-to-moderate affinity. Compared to a full agonist like diazepam (Ki ~10 nM), chrysin's affinity is in the micromolar range, and even at saturating concentrations chrysin produces only a fraction of the maximal positive modulation that diazepam produces. This is exactly the pharmacology one would design for a gentle anxiolytic: enough BDZ-site occupation to amplify GABAergic inhibition modestly, but never enough to clamp the chloride channel and produce the cognitive impairment, motor incoordination, amnestic effect, and dependence liability of full benzodiazepine agonists.

Bioavailability is a significant constraint. Chrysin has poor oral bioavailability in humans (typically < 1% reported in pharmacokinetic studies), with extensive first-pass metabolism producing chrysin glucuronide and sulfate conjugates. This raises the legitimate question of whether enough free chrysin reaches the brain after an oral passionflower dose to account for the clinical effect. The answer is probably partly chrysin and partly the other actives discussed below — benzoflavones, additional flavone aglycones, and the still-undefined contribution of the harman alkaloids. The whole-extract is more active than isolated chrysin would predict, consistent with multi-component synergy.

Back to Table of Contents

Benzoflavones: The Second Active Scaffold

Dhawan and colleagues searched Passiflora incarnata methanol extract by bioassay-guided fractionation. Their 2001 study found a fraction with significant anxiolytic activity at 10 mg/kg in mice in the elevated plus maze, and proposed that a compound with a benzoflavone nucleus was responsible; later papers by the same author describe a tri-substituted benzoflavone moiety (BZF) isolated from the extract. The benzoflavone is structurally distinct from chrysin — an additional fused benzene ring extends the flavone scaffold.

An independent laboratory (Holbik and colleagues, 2010) then tried to isolate the compound from passionflower herb grown in India, Italy and France. A compound with the published characteristics was found in trace amounts only in the Italian material, and no traces were found in the Indian or French herb. The authors concluded that the benzoflavone is not the active principle of the herb and should not serve as an active marker.

Studies by Dhawan, summarised in a 2003 review of the author's own work, reported for the benzoflavone moiety:

The mechanism by which the benzoflavone produces these diverse effects is not fully characterized but likely involves modulation of multiple receptor systems including the gamma-aminobutyric acid-A receptor, possibly the cannabinoid CB1 receptor (theorized but not confirmed), and downstream effects on stress-hormone axes. The reversal-of-tolerance effects across opiate, nicotine, and cannabinoid models is a particularly intriguing common-pathway finding that has guided the use of passionflower in addiction medicine.

Standardization of passionflower extracts to benzoflavone content (rather than chrysin or vitexin) has been proposed by some authors as more clinically meaningful, but commercial standardization remains heterogeneous — some products specify vitexin equivalents, others specify total flavonoid content, others use no standardization at all. The independent 2010 analysis described above concluded that the benzoflavone should not serve as an active marker.

Back to Table of Contents

Comparison: Apigenin (Chamomile) and Bacopa

Several other widely used botanical anxiolytics work through the same gamma-aminobutyric acid-A benzodiazepine binding site as chrysin, with structurally similar flavone scaffolds:

The therapeutic implication of this large family of gamma-aminobutyric acid-A modulating flavones is that combination herbal formulations can layer multiple low-affinity ligands to produce additive effect without redundancy. A formulation containing passionflower + chamomile + skullcap may produce more robust anxiolysis than any single herb alone at comparable total dose, while maintaining the cognitive-preservation profile of partial-agonist pharmacology.

Back to Table of Contents

Non-Benzodiazepine-Site Gamma-Aminobutyric Acid-A Modulation

An important pharmacologic nuance: not all of passionflower's activity on the gamma-aminobutyric acid system runs through the benzodiazepine binding site. The Appel 2011 laboratory study tested a dry extract of Passiflora incarnata on rat brain tissue. The extract slowed the uptake of gamma-aminobutyric acid into rat cortical nerve endings (synaptosomes), but did not change its release or its breakdown by the enzyme GABA transaminase. It blocked radioligand binding at both gamma-aminobutyric acid-A and gamma-aminobutyric acid-B receptors, and in a further assay it behaved as a gamma-aminobutyric acid-B receptor antagonist (blocker). The benzodiazepine site and the ethanol (alcohol) site of the gamma-aminobutyric acid-A receptor were not affected by the extract.

The Elsas 2010 study, in hippocampal brain slices, found that whole passionflower extract produced prominent, dose-dependent direct gamma-aminobutyric acid-A currents, but not the expected modulation of synaptic gamma-aminobutyric acid-A currents. The currents came from gamma-aminobutyric acid contained in the extract itself (see GABA Itself Is in the Extract).

Back to Table of Contents

Harman Beta-Carboline Alkaloids and MAO-A

Beyond flavonoids, Passiflora incarnata contains trace amounts of beta-carboline alkaloids in the harman family — harman (1-methyl-beta-carboline), harmine (1-methyl-7-methoxy-beta-carboline), harmaline (the dihydro analog of harmine), and harmol (the 7-hydroxy analog). These compounds are weak reversible inhibitors of monoamine oxidase A (MAO-A), the enzyme that catabolizes serotonin, norepinephrine, and dietary tyramine.

The harman alkaloid content in passionflower is low — typically reported in the range of 0.01-0.1% of dried herb weight, with substantial variation across cultivars, growing conditions, and harvest timing. The pharmacologically relevant concentrations achieved with normal therapeutic passionflower doses are well below those required to produce clinically meaningful MAO inhibition in vivo. For comparison, the same beta-carboline alkaloids in much higher concentration in the Amazonian vine Banisteriopsis caapi (ayahuasca) do produce potent MAO-A inhibition, but at orders-of-magnitude higher concentration than is achieved with normal passionflower dosing.

That said, the presence of these alkaloids creates a theoretical concern for drug interactions:

The Avula 2012 work developed a UPLC method that measures five beta-carboline (indole) alkaloids and four flavonoids together in several Passiflora species and in dietary supplements that claim to contain Passiflora, providing an analytical basis for quality-control standardization. Most clinical concerns about MAO-mediated interactions are theoretical rather than documented in practice; the actual clinical safety record of passionflower in routine use is excellent.

Back to Table of Contents

Why Partial Agonism Produces Gentler Effects

The partial-agonist character of chrysin and benzoflavones at the gamma-aminobutyric acid-A benzodiazepine site is the central mechanistic explanation for passionflower's gentler clinical profile relative to prescription benzodiazepines. The pharmacologic principle:

The partial-agonist profile also has a self-limiting ceiling on effect: increasing the dose beyond a certain point does not produce proportionally more anxiolysis because the inherent intrinsic activity of the molecule is limited. This is why passionflower has an excellent overdose safety profile — it is essentially impossible to produce life-threatening respiratory depression with passionflower alone, in contrast to benzodiazepines (especially in combination with opioids or alcohol).

The trade-off is that severe acute anxiety, panic attacks, status epilepticus, or severe insomnia — situations that require maximal gamma-aminobutyric acid-A potentiation — will not be adequately treated by passionflower or any partial-agonist botanical. Full benzodiazepine agonism remains the standard for these acute indications.

Back to Table of Contents

Tolerance, Dependence, and Withdrawal Profile

The published clinical and observational evidence base for passionflower does not document significant tolerance development, physiologic dependence, or withdrawal syndrome with chronic use. This is mechanistically consistent with the low-occupancy, partial-agonist binding profile:

A 2020 systematic review of nine randomized clinical trials, lasting from one day up to 30 days in adults, found that most reported reduced anxiety after passionflower preparations, with the effect less evident in people with mild anxiety symptoms. No adverse effects, including memory loss or collapse of psychometric functions, were observed.

This favorable profile is one of the main reasons passionflower has a legitimate role in benzodiazepine tapering protocols, where its mild gamma-aminobutyric acid-A potentiation can help ease the rebound anxiety and insomnia of taper without becoming a substitute dependence target.

Back to Table of Contents

Flumazenil Blocked Chrysin and the Whole Extract in Mice

Flumazenil is a pharmaceutical antagonist at the gamma-aminobutyric acid-A benzodiazepine binding site, used in the emergency department to reverse benzodiazepine overdose. A purely BDZ-site ligand should have its effect completely blocked by flumazenil pretreatment.

In a 2008 mouse study, a characterized Passiflora incarnata extract given by mouth at 375 mg/kg had an anxiolytic effect in the elevated plus maze comparable to diazepam (1.5 mg/kg), with a U-shaped dose-response curve. Flumazenil effectively blocked this effect, while the serotonin 5-HT1A receptor blocker WAY-100635 did not. The Wolfman 1994 work with isolated chrysin likewise found that pretreatment with flumazenil (Ro 15-1788) abolished chrysin's effect in the elevated plus maze, consistent with BDZ-site action. Neither the Appel 2011 nor the Elsas 2010 study tested flumazenil.

These animal results sit alongside the laboratory findings above: in rat brain tissue the extract slowed gamma-aminobutyric acid uptake and bound gamma-aminobutyric acid-A and gamma-aminobutyric acid-B receptors without acting at the benzodiazepine site (Appel 2011), and gamma-aminobutyric acid contained in the extract produced direct gamma-aminobutyric acid-A currents in brain slices (Elsas 2010). Passionflower extract therefore acts on the gamma-aminobutyric acid system in more than one way, and the whole-extract pharmacology is more complex than isolated chrysin would predict. A 2011 review of flavonoids and gamma-aminobutyric acid-A receptors lists flumazenil-insensitive modulation by some flavonoids as one area of research interest.

The findings also fit the general principle that whole-plant botanical pharmacology is rarely reducible to a single isolated active compound.

Back to Table of Contents

Theoretical and Real Drug Interaction Concerns

A laboratory study published in 2026 found that a standardized passionflower extract also bound adenosine A1, adenosine A2A and serotonin 5-HT2A receptors (but not melatonin MT1 or orexin OX1 receptors), and slowed the uptake of dopamine, norepinephrine and serotonin into rat brain nerve endings — actions beyond the gamma-aminobutyric acid system that bear on the serotonin-interaction question above. It was an exploratory test-tube study; it did not test people.

Back to Table of Contents

GABA Itself Is in the Extract

A 2010 study (Elsas and colleagues) found that gamma-aminobutyric acid itself is a prominent ingredient of passionflower extract. Whole extract produced prominent, dose-dependent gamma-aminobutyric acid-A currents in hippocampal brain slices, and these currents were absent when the amino acids were removed from the extract.

The same study showed that the way the herb is extracted changes what is in it: from the same batch of plant material, hot extraction gave substantially higher total flavonoid yields than cold extraction. Five different extracts from a single batch were then given to mice in their drinking water for one week. Two of the five protected the mice against chemically induced (pentylenetetrazol) seizures. Instead of the anxiolytic effects described by other groups, all five extracts produced more anxiety-like behaviour (anxiogenic effects) in the elevated plus maze.

Back to Table of Contents

Key Research Papers

  1. Medina JH, Paladini AC, Wolfman C, Levi de Stein M, Calvo D, Diaz LE, Pena C (1990). Chrysin (5,7-di-OH-flavone), a naturally occurring ligand for benzodiazepine receptors, with anticonvulsant properties. Biochemical Pharmacology, 40(10), 2227-2231. — PubMed PMID: 2173925
  2. Wolfman C, Viola H, Paladini A, Dajas F, Medina JH (1994). Possible anxiolytic effects of chrysin, a central benzodiazepine receptor ligand isolated from Passiflora coerulea. Pharmacology Biochemistry and Behavior, 47(1), 1-4. — PubMed PMID: 7906886
  3. Dhawan K, Kumar S, Sharma A (2001). Anti-anxiety studies on extracts of Passiflora incarnata Linneaus. Journal of Ethnopharmacology, 78(2-3), 165-170. — PubMed PMID: 11694362
  4. Dhawan K, Dhawan S, Sharma A (2004). Passiflora: a review update. Journal of Ethnopharmacology, 94(1), 1-23. — PubMed PMID: 15261959
  5. Marder M, Paladini AC (2002). GABA-A-receptor ligands of flavonoid structure. Current Topics in Medicinal Chemistry, 2(8), 853-867. — PubMed PMID: 12171576
  6. Appel K, Rose T, Fiebich B, Kammler T, Hoffmann C, Weiss G (2011). Modulation of the gamma-aminobutyric acid (GABA) system by Passiflora incarnata L. Phytotherapy Research, 25(6), 838-843. — PubMed PMID: 21089181
  7. Elsas SM, Rossi DJ, Raber J, White G, Seeley CA, Gregory WL, Mohr C, Pfankuch T, Soumyanath A (2010). Passiflora incarnata L. (passionflower) extracts elicit GABA currents in hippocampal neurons in vitro, and show anxiogenic and anticonvulsant effects in vivo, varying with extraction method. Phytomedicine, 17(12), 940-949. — PubMed PMID: 20382514
  8. Salgueiro JB, Ardenghi P, Dias M, Ferreira MB, Izquierdo I, Medina JH (1997). Anxiolytic natural and synthetic flavonoid ligands of the central benzodiazepine receptor have no effect on memory tasks in rats. Pharmacology Biochemistry and Behavior, 58(4), 887-891. — PubMed PMID: 9408191
  9. Avula B, Wang YH, Rumalla CS, Smillie TJ, Khan IA (2012). Simultaneous determination of alkaloids and flavonoids from aerial parts of Passiflora species and dietary supplements using UPLC-UV-MS and HPTLC. Natural Product Communications, 7(9), 1177-1180. — PubMed PMID: 23074901
  10. Sigel E, Steinmann ME (2012). Structure, function, and modulation of GABA-A receptors. Journal of Biological Chemistry, 287(48), 40224-40231. — PubMed PMID: 23038269
  11. Hanrahan JR, Chebib M, Johnston GA (2011). Flavonoid modulation of GABA(A) receptors. British Journal of Pharmacology, 163(2), 234-245. — PubMed PMID: 21244373
  12. Johnston GA (2015). Flavonoid nutraceuticals and ionotropic receptors for the inhibitory neurotransmitter GABA. Neurochemistry International, 89, 120-125. — PubMed PMID: 26190180
  13. Dhawan K, Kumar S, Sharma A (2002). Beneficial effects of chrysin and benzoflavone on virility in 2-year-old male rats. Journal of Medicinal Food, 5(1), 43-48. — PubMed PMID: 12511112
  14. Dhawan K (2003). Drug/substance reversal effects of a novel tri-substituted benzoflavone moiety (BZF) isolated from Passiflora incarnata Linn.—a brief perspective. Addiction Biology, 8(4), 379-386. — PubMed PMID: 14690874
  15. Holbik M, Krasteva S, Mayer N, Kählig H, Krenn L (2010). Apparently no sedative benzoflavone moiety in passiflorae herba. Planta Medica, 76(7), 662-664. — PubMed PMID: 20301055
  16. Grundmann O, Wang J, McGregor GP, Butterweck V (2008). Anxiolytic activity of a phytochemically characterized Passiflora incarnata extract is mediated via the GABAergic system. Planta Medica, 74(15), 1769-1773. — PubMed PMID: 19006051
  17. Janda K, Wojtkowska K, Jakubczyk K, Antoniewicz J, Skonieczna-Żydecka K (2020). Passiflora incarnata in Neuropsychiatric Disorders-A Systematic Review. Nutrients, 12(12), 3894. — PubMed PMID: 33352740
  18. Appel K, Schwarzensteiner I, Zimmermann C, Tober C, Günnewich N (2027). A Passiflora incarnata extract exerts multi-target effects on selected sleep-related receptors. Journal of Ethnopharmacology, 372, 122198 (published online 2026). — PubMed PMID: 42462921

PubMed Topic Searches

  1. PubMed: Chrysin BDZ receptor
  2. PubMed: Passiflora benzoflavone
  3. PubMed: Flavonoid GABA-A partial agonist
  4. PubMed: Harman MAO-A inhibition
  5. PubMed: Passiflora flumazenil reversal

Back to Table of Contents

Connections

Back to Table of Contents